证券日报网讯 12月17日，华特达因在互动平台回答投资者提问时表示，达因药业目前产品生产质量体 系对标国际标准，两条生产线已通过澳大利亚TGA认证，并取得最高的A1等级，为国际化奠定了一定 基础，但目前仍主要基于我国儿童临床和营养健康需求，通过选择海外优质产品或原料引入国内开展跨 境业务，基本没有出海业务收入。 （文章来源：证券日报） ...

华特达因（000915.SZ）12月17日在投资者互动平台表示，达因药业目前产品生产质量体系对标国际标 准，两条生产线已通过澳大利亚TGA认证，并取得最高的A1等级，为国际化奠定了一定基础，但目前 仍主要基于我国儿童临床和营养健康需求，通过选择海外优质产品或原料引入国内开展跨境业务，基本 没有出海业务收入。 （记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：目前公司伊可新产品的海外业务进展如何？ ...

证券日报网讯12月2日，华特达因（000915）在互动平台回答投资者提问时表示，公司会根据市场需求 灵活调整生产及销售，目前公司的小儿布洛芬栓和伊可新AD剂等市场需求稳定。公司会持续关注市场 动态，公司现有生产完全能够满足市场对各类产品的需求。 ...

Core Viewpoint - The company, Huate Dain (000915.SZ), has stated on its interactive platform that it currently does not have any montmorillonite powder products available [1] Company Summary - Huate Dain has confirmed the absence of montmorillonite powder products in its offerings [1]

Core Viewpoint - The 2024 Golden Bull Award for Dividend Return was awarded to Huate Dain, a company focused on the pharmaceutical industry, emphasizing its commitment to children's health and high-quality development [1][2]. Group 1: Event Overview - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu on October 29 [1]. - The theme of the forum was "Moving Forward with New Initiatives, Achieving Long-Term Goals through Practical Actions, and Innovating for the Future" [1]. Group 2: Award Details - The Golden Bull Award is a prestigious evaluation activity organized by China Securities Journal, established in 1999, focusing on transparency and professionalism [1]. - This year's awards included nine categories, such as "Most Investment Value Award," "Golden Bull Listed Company Dividend Return Award," and "Golden Bull Secretary Award" [2]. - The "Golden Bull Listed Company Dividend Return Award" was based on key indicators like total dividends, dividend yield, and frequency of dividends over recent years, resulting in the recognition of 60 listed companies [2].

Group 1 - The core viewpoint of the article is that Huate Dain (华特达因) clarified that there is currently no research and collaboration on long-acting insulin analog products with its subsidiary Dain Pharmaceutical and the Chinese Academy of Medical Sciences [2] Group 2 - Investors inquired about the strategic cooperation agreement between Dain Pharmaceutical and the Chinese Academy of Medical Sciences, specifically regarding long-acting insulin analog products expected to enter clinical trials next year [2] - Huate Dain responded on the investor interaction platform, stating that there are no ongoing developments or collaborations related to the mentioned long-acting insulin analog products [2]

Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance [1] Financial Performance - The company achieved a revenue of 432,116,216.88 yuan in the third quarter of 2025, representing a year-on-year growth of 93.28% [1] - The net profit attributable to shareholders was 70,598,114.55 yuan, showing a year-on-year increase of 110.42% [1]

Core Insights - The company reported a revenue of 1.603 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 16.30% [1] - The net profit attributable to shareholders reached 408 million yuan, with a year-on-year increase of 11.67% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 400 million yuan, showing a year-on-year growth of 15.80% [1]

Company Performance - Huate Dain reported Q3 performance with revenue of approximately 1.603 billion yuan, an increase of 16.3% year-on-year [1] - The net profit attributable to shareholders was about 408 million yuan, reflecting an increase of 11.67% year-on-year [1] - Basic earnings per share reached 1.7414 yuan, also up by 11.67% year-on-year [1] Market Context - As of the report, Huate Dain's market capitalization stands at 7.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2]

Core Viewpoint - 华特达因 reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong operational performance and financial health [1] Financial Performance - The company's operating revenue reached 432 million yuan, representing a year-on-year increase of 93.28% [1] - The net profit attributable to shareholders was 70.6 million yuan, showing a year-on-year growth of 110.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 67.3 million yuan, reflecting a year-on-year increase of 153.51% [1]